BD Rolls Out CentroVena One Central Venous Catheter Insertion System

BD (Becton, Dickinson and Company) has commercially launched its CentroVena One insertion system, which it markets as the first all-in-one central venous catheter (CVC) insertion device in the industry.

The company said the system was engineered to simplify central line placement for clinicians and boost safety for patients by streamlining crucial steps and incorporating safety-focused design elements to support care in acute settings.

CentroVena One consolidates the introducer needle, syringe, guidewire, and catheter into one platform. BD said the approach was designed to create 30% fewer steps and cut insertion time in half. The system also minimizes touchpoints during insertion to reduce contamination risk and protects against insertion-related complications.

Features include a preloaded kink-resistant guidewire to which an integrated drape clip is permanently attached to help prevent embolism, as well as a preloaded catheter with a self-dilating tip to remove the need for a separate dilation step. The introducer needle boasts integrated passive needle safety to reduce injury risk and a closed insertion system helps lower risk of air embolism, blood exposure, and blood loss.

“Central line placement is one of the highest-pressure bedside procedures our teams perform—especially in fast-moving, high-acuity environments where unpredictability is inherent and skilled clinicians must bring precision to complexity in real time,” said Anthony Frank, MD, MBA, FACEP, chief medical officer and senior vice president of Medical Affairs at UNC Health Blue Ridge. “What stands out in our early experience with CentroVena One is its intentional design around real-world clinical challenges – streamlining catheter placement while reducing opportunities for error, sterile field breaches and overall workload. Innovations that better support frontline teams in this way align directly with our commitment to patient safety, high-quality care and infection prevention.”

CentroVena One recently earned U.S. Food and Drug Administration (FDA) 510(k) clearance and was accepted into the FDA Safer Technologies Program (STeP) for Medical Devices. Its launch marks BD’s arrival into the acute CVC market.

“CentroVena One represents the most meaningful advancement in central line insertion since the technique was first introduced nearly seven decades ago,” said Ron Silverman, executive VP and chief medical officer at BD. “By reducing procedural steps, helping protect against preventable complications and simplifying one of the most stressful procedures clinicians perform, we’re supporting safer, faster care for patients when every second counts.”